Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Brain Neoplasms × cobimetinib × Clear all

Phase

Status

Terminated 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1 CNS 1

Conditions

Melanoma 8 Breast Neoplasms 3 Thyroid Neoplasms 1 Thrombocytosis 1 Prostatic Neoplasms 1 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1 Leukemia, Myeloid, Acute 1 Leukemia, Myeloid, Accelerated Phase 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hodgkin Disease 1 Hematologic Neoplasms 1 Glioblastoma 1 Gastrointestinal Neoplasms 1 Colorectal Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Temozolomide 28 Radiotherapy 16 Radiosurgery 16 Bevacizumab 11 Magnetic Resonance Spectroscopy 7 Erlotinib Hydrochloride 6 Carboplatin 6 Topotecan 5 Radiation 5 Irinotecan 5 Capecitabine 5 dabrafenib 4 Trastuzumab 4 Pemetrexed 4 Mental Status and Dementia Tests 4 Filgrastim 4 Aminolevulinic Acid 4 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 4 pembrolizumab 3 cabozantinib 3 TPI-287 3 Sunitinib 3 Specimen Handling 3 Radiotherapy, Intensity-Modulated 3 Nivolumab 3 Methylphenidate 3 Granulocyte Colony-Stimulating Factor 3 Cyclophosphamide 3 Carmustine 3 trametinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03430947 2023-09-14

RadioCoBRIM

Technische Universität Dresden

Phase 2 Terminated

CNSDermatologic

Brain Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡